Iozomic Acid is triiodobenzoic acid derivative patented by Pharmacia Aktiebolag as X-ray contrast agent for Coronary Angiography.

Odalprofen was used as an analgesic. Information about the current use of this compound is not available.

LASCUFLOXACIN, a fluoroquinolone derivative, is an antibacterial agent with a broad spectrum of activity against various clinical isolates. It is under development for the treatment of respiratory tract infections and community-acquired pneumonia.

Xorphanol (also known as TR5379M) is a full κ-opioid receptor agonist and is a partial agonist at μ opioid receptor. Clinically, xorphanol was studied as an orally active analgesic that provided effective pain relief but showed low physical dependence liability. Further development of this drug was discontinued.

LEIOPYRROLE is an antispasmodic agent.

LANIQUIDAR is a P-glycoprotein inhibitor. It was used in trials studying the treatment of breast cancer.

Dulofibrate is a fibrate derivative with antilipidemic activity. Unlike clofibrate, dulofibrate is selective for a reduction in triglycerides. Dulofibrate decreased the conjugation of nopol. Dulofibrate exhibited a clofibrate-like effect on the induction of hepatic drug-metabolizing enzymes, characterized by an increase in lauric acid 12-hydroxylation and bilirubin UDP-glucuronosyltransferase activities. Dulofibrate and fenofibrate have been shown to possess an equal potency as peroxisome proliferators.

Sotrastaurin, an orally-active, first-in-class immunomodulator, is under development by Novartis for the treatment of uveal melanoma and diffuse-large B-cell lymphoma. Sotrastaurin is a low molecular mass synthetic compound that potently inhibits the PKC α, β and the θ isoforms resulting in selective NF-κB inactivation. Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM in a cell-free assay. Inhibition of PKC beta in B-cells results in prevention of NF-kB-mediated signaling and down regulation of NF-kB target genes. This may eventually lead to an induction of G1 cell cycle arrest and tumor cell apoptosis in susceptible tumor cells. This agent may act synergistically with other chemotherapeutic agents. PKC, a family of serine/threonine protein kinases overexpressed in certain types of cancer cells, is involved in cell differentiation, mitogenesis, inflammation, and the activation and survival of lymphocytes. Sotrastaurin is currently in phase II trials by Novartis for the treatment of large B-cell lymphoma and uveal melanoma. Sotrastaurin was in Phase II of clinical development for the prevention of acute rejection after solid organ transplantation and psoriasis, but this reseach had being discontinued.